Type 2 Diabetes Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A person must have signed a consent form before taking part in any study-related activities.
- The decision to start treatment with the insulin icodec must have been made by the person (or their legal representative) and their treating doctor before and separately from any decision to join this study.
- People aged 18 years or older at the time of signing the consent form.
- People who have been diagnosed with type 2 diabetes for at least 1 year before signing the consent form.
- People who have been treated with once- or twice-daily basal insulin injections for at least 6 months before signing the consent form — other diabetes medications are allowed, except for fast-acting (bolus) insulin used for 14 days or more in the 90 days before switching to icodec.
- A recent blood sugar control test result (called HbA1c) must be available, either from within the 90 days before the first study visit, or taken at the time of that visit if that fits with local medical practice.
- People who have not previously been treated with a once-weekly insulin before the first study visit.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously taken part in this same study by having already signed a consent form for it.
- People who have been treated with an experimental drug within the 30 days before enrolling in the study.
- People who have difficulty understanding or cooperating due to mental capacity, unwillingness, or language barriers.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in glycated haemoglobin (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.